6,463 reports of this reaction
3.2% of all TOPIRAMATE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for TOPIRAMATE, manufactured by Janssen Pharmaceuticals, Inc.. There are 6,463 FDA adverse event reports linking TOPIRAMATE to HEADACHE. This represents approximately 3.2% of all 203,737 adverse event reports for this drug.
TOPIRAMATE has an overall safety score of 85 out of 100. Patients taking TOPIRAMATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among TOPIRAMATE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for TOPIRAMATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 6,463 FDA reports for TOPIRAMATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.2% of all adverse event reports for TOPIRAMATE, making it one of the most commonly reported side effect.
If you experience headache while taking TOPIRAMATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.